Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs PubMatic Inc (PUBM) Price & Performance

Cassava Sciences IncTrade
PubMatic IncTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs PubMatic Inc — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while PubMatic Inc trades at $17.52 (market cap $808.97M). The key difference: PubMatic Inc is far larger — about 16.9× Cassava Sciences Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNAPUBM
Market Cap
$47.75M$808.97M
Sector
HealthTechnology
52-Week High
$4.64$17.78
52-Week Low
$0.87$6.28
Enterprise Value
-$34.93M$712.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

PubMatic Inc

PUBM's stock surged 31.9% to $17.78, reflecting strong investor optimism following a Q2 2026 earnings beat with 10.5% revenue growth and improved profitability in mobile app and CTV segments. Technical indicators show a bullish trend with support at $17 and resistance at $18, though RSI levels suggest overbought conditions. The company maintains a robust balance sheet with $120M in cash and positive operating cash flow of $81.06M in 2025, despite a net loss of -$14.46M. Recent leadership changes, including the appointment of a new Global Chief Revenue Officer, aim to accelerate growth amid AI-driven advertising transformations.

The outlook for PUBM is cautiously optimistic, with a consensus price target of $21.50 offering 21% upside potential. Key opportunities include double-digit revenue growth in high-margin segments and AI product adoption, but risks persist from competitive pressures, profitability challenges, and reliance on digital advertising cyclicality. Investors should weigh the strong analyst buy ratings against elevated valuation multiples and execution risks in a dynamic market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About PubMatic Inc

PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.

Read more on PUBM